From: Gut microbiota and cardiac arrhythmia: a pharmacokinetic scope
 | Major route of elimination | Involved cytochrome P450 enzymes | Protein binding % | Transporters | References | ||
---|---|---|---|---|---|---|---|
Anti-arrhythmic Drugs | Class Ia | Quinidine | Hepatic and renal | CYP3A4, CYP2D6 | 80 | P-glycoprotein, OCT2, OCT3 | |
Disopyramide | Renal | CYP3A4 | 50–65 | OCT2, OCT3 | [53] | ||
Procainamide | Hepatic and renal | CYP2D6 | 20 | MATE; OCT3 | |||
Class Ib | Lidocaine | Hepatic | CYP1A2, CYP3A4 | 60–80 | OCT3 | ||
Phenytoin | Hepatic | CYP2C19; CYP2C9 | 90 | OCT3 | |||
Mexiletine | Hepatic | CYP2D6 | 70 | OCT2, OCT3 | |||
Tocainide | Hepatic and renal | CYP3A4 | 50 | Â | [60] | ||
Class Ic | Flecainide | Hepatic and renal | CYP2D6 | 20 | OCT2 | ||
Propafenone | Hepatic | CYO2D6, CYP3A4 | 90 | OCT2 | |||
Class II | Esmolol | Blood esterase | ……. | 55 |  | [63] | |
Metoprolol | Hepatic | CYP2D6 | Â | Â | [64] | ||
Class III | Amiodarone | Hepatic | CYP1A2, CYP2C9, CYP2D6 | 96 | P-glycoprotein, OAT2B1 | ||
Sotalol | Renal | CYP3A4 | 0 | OCT2 | |||
Ibutilide | Hepatic and renal | undetermined | … |  | [67] | ||
Dofetilide | Hepatic and renal | CYP3A4 | 60–70 | MATE: OCT2 | |||
Class IV | Verapamil | Hepatic | CYP3AF, CYP3A5 | 90 | P-glycoprotein, OCT2 | ||
Diltiazem | Hepatic | CYP3AF, CYP3A5 | 70–80 | P-glycoprotein | |||
Others | Adenosine | Cellular metabolism | …… | …… |  | [69] | |
Digoxin | Renal | …… | 20–30 | P-glycoprotein | |||
Antithrombotic | Warfarin | Hepatic | CYP1A2, CYP2C19, CYP3A4 | 99 | Â | [71] | |
Aspirin* | Hepatic | CYP2D9 | 58.3–81.7# | OAT1 | |||
Dabigatran | Renal | CYP3A4 | 35 | P-glycoprotein | |||
Edoxaban | Renal | …. | 40–59 | P-glycoprotein | |||
Rivaroxaban | Hepatic and renal | CYP3A4, CYP3A5, CYP2J2 | 92–95 | P-glycoprotein | |||
Apixaban | Hepatic and renal | CYP3A4, CYP1A2, 2C8, 2C9, 2C19 | 93 | P-glycoprotein |